Searched for
SECIERA
Sun Pharma rises with R&D and bets on specialty drugsSun Pharma- India's largest drug maker - is vying for its share in the US$9 billion market through a drug, Ilumya, that treats moderate-to-...- Beyond Sun's pain is a promise of specialty segment: AnalystsSome analysts suggested that investors willing to overlook the subdued outlook.
- Sun Pharma hits 44-month low, down 24% in 7 sessions; what experts sayThe stock fell 12.84 per cent to hit a 44-month low of Rs 495.55 amid weak fourth quarter results.
- Sun Pharma Q3 net profit slips 4.7% YoY to Rs 1,471.82 croreSales for the quarter came in at Rs 7,683.24 crore, compared with Rs 7,087.07 crore in the same quarter last year.
- Market hits 2-month high on firm global cues, Sensex jumps 245 pts, Nifty above 8,250Metal stocks remained in demand after copper edged higher in global commodities markets. JSW Steel, Jindal Steel, Vedanta and Tata Steel ga...
- Fourteen stocks in focus on Thursday, 5 January 2017Tech Mahindra on Wednesday launched a majority-owned joint venture in Saudi Arabia in partnership with local conglomerate Al Fozan Group
- Sun Pharma announces positive results in phase 3 study of eye care drugSeciera is a patented, novel drug developed by Ocular Technologies, a company recently acquired by Sun Pharma. This acquisition gave Sun Ph...
- Sun Pharma completes acquisition of Ocular Technologies SarlAll the necessary formalities for closure of the said transaction have been concluded and the company has successfully completed the acquis...
- Sun Pharma launches first branded drug BromSite in USThe launch marks Sun Pharma’s entry into the branded drugs business in the US, a segment that many generic drug companies are targeting as ...
- Sun Pharma to buy Ocular Technologies from Auven TherapeuticsSun will pay Auven $40 million upfront, contingent development milestones and sales milestones, in addition to royalties on sales of Secier...
Load More
